Amylyx Pharmaceuticals (NASDAQ:AMLX) Issues Earnings Results

Amylyx Pharmaceuticals (NASDAQ:AMLX) released its quarterly earnings data on Thursday. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.03), FiscalAI reports.

Here are the key takeaways from Amylyx Pharmaceuticals’ conference call:

• LUCIDITY top-line data is expected in late August or early September 2026 after the final participant completed the 16-week study period; database cleaning and locking are still underway, and management remains blinded to the results.
• Amylyx reported $250.8 million in cash and marketable securities at quarter-end and expects its cash runway to extend into 2028, covering anticipated avexitide milestones, including a potential 2027 launch.
• Commercial preparations are advancing ahead of a potential avexitide approval, including field medical deployment, key commercial hires, an HCP and patient education campaign, and plans to target treatment centers with concentrated PBH populations.
• Management estimates approximately 160,000 U.S. patients have post-bariatric hypoglycemia and cites high endocrinologist intent to treat with an approved therapy; a dedicated ICD-10 code becomes effective October 1, 2026, potentially improving recognition and tracking of the condition.
• Q2 operating expenses rose 7% year over year to $45.7 million, driven partly by higher legal costs, including a one-time charge, and increased commercial investment; avexitide’s approval, label breadth, and launch timing remain dependent on the pending phase III data and FDA review.

Amylyx Pharmaceuticals Trading Down 5.7%

Shares of Amylyx Pharmaceuticals stock traded down $1.37 during trading on Friday, reaching $22.82. The company’s stock had a trading volume of 2,678,272 shares, compared to its average volume of 1,419,705. The stock has a 50-day moving average price of $17.19 and a two-hundred day moving average price of $15.71. The stock has a market capitalization of $2.54 billion, a P/E ratio of -15.21 and a beta of -0.21. Amylyx Pharmaceuticals has a one year low of $7.48 and a one year high of $24.60.

Analysts Set New Price Targets

Several analysts recently commented on the company. Wall Street Zen lowered Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Citigroup lifted their price objective on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a “buy” rating in a report on Monday. HC Wainwright restated a “buy” rating and issued a $34.00 target price on shares of Amylyx Pharmaceuticals in a research note on Monday, June 8th. Guggenheim raised their price objective on shares of Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, June 25th. Finally, Mizuho lifted their target price on shares of Amylyx Pharmaceuticals from $21.00 to $24.00 and gave the company an “outperform” rating in a research note on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amylyx Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.38.

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 15,000 shares of the firm’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $18.32, for a total value of $274,800.00. Following the completion of the sale, the insider owned 194,090 shares in the company, valued at approximately $3,555,728.80. This trade represents a 7.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 10.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Adage Capital Partners GP L.L.C. boosted its position in Amylyx Pharmaceuticals by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock valued at $56,408,000 after buying an additional 3,102,395 shares during the last quarter. Perceptive Advisors LLC lifted its stake in shares of Amylyx Pharmaceuticals by 0.4% during the second quarter. Perceptive Advisors LLC now owns 7,902,365 shares of the company’s stock valued at $50,654,000 after acquiring an additional 28,017 shares during the period. TCG Crossover Management LLC lifted its stake in shares of Amylyx Pharmaceuticals by 5.0% during the third quarter. TCG Crossover Management LLC now owns 6,243,812 shares of the company’s stock valued at $84,853,000 after acquiring an additional 300,000 shares during the period. Janus Henderson Group PLC boosted its holdings in Amylyx Pharmaceuticals by 76.1% in the fourth quarter. Janus Henderson Group PLC now owns 4,465,872 shares of the company’s stock valued at $53,992,000 after acquiring an additional 1,929,639 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in Amylyx Pharmaceuticals by 418.6% in the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock valued at $10,910,000 after acquiring an additional 2,487,617 shares during the last quarter. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.